日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global cancer statistics for children: Two decades of change and projections to 2050

全球儿童癌症统计数据:二十年来的变化及至2050年的预测

Li, Wangzhong; Huang, Shanzhou; Chen, Qiyue; Wang, Ting; Lu, Guanming; Niu, Xing; Song, Qiong; Xu, Yilin; Mo, Ke; Cui, Chunhui; Zhang, Run; Du, Wei; He, Feiying; Shi, Lei; Lin, Yan; Wei, Qiu; Jiang, Li; Chen, Yongsheng; Song, Baiyang; Zhang, Huijuan; Fu, Zhenli; Liao, Wenjing; Sun, Jiancong; Guan, Wenhui; Zhuang, Weitao; Zhong, Nanshan; Zhou, Chengzhi; Liang, Wenhua; Kang, Min; He, Jianxing

Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.

在 NF1 突变型乳腺癌中,通过诱导多能干细胞衍生的多器官类器官平台进行个性化药代动力学-药效学指导治疗。

Lim Jung Hwa, Mun Seon Ju, Kang Hyun Mi, Yu Won Dong, Oh Soo Jin, Lee Ji-Yoon, Son Ye Seul, Lee Sugi, Kim Dae Soo, Lee Jaeseo, Kim Su Jeong, Cho Hyun-Soo, Son Myung Jin, Son Mi-Young, Jung Cho-Rok

Targeting FSP1 triggers ferroptosis in lung cancer

靶向FSP1可诱导肺癌细胞发生铁死亡

Katherine Wu #,Alec J Vaughan #,Jozef P Bossowski,Yuan Hao,Aikaterini Ziogou,Seon Min Kim,Tae Ha Kim,Mari N Nakamura,Ray Pillai ,Mariana Mancini,Sahith Rajalingam,Mingqi Han,Toshitaka Nakamura,Lidong Wang,Suckwoo Chung,Diane Simeone,David Shackelford,Yun Pyo Kang,Marcus Conrad,Thales Papagiannakopoulos

CLCC1 promotes hepatic neutral lipid flux and nuclear pore complex assembly.

CLCC1促进肝脏中性脂质通量和核孔复合物组装。

Mathiowetz Alyssa J, Meymand Emily S, Parlakgül Güneş, van Hilten Niek, Torres Emily F, Artico Leonardo L, Deol Kirandeep K, Lange Mike, Pang Stephany P, Doubravsky Cody E, Roberts Melissa A, Jorgens Danielle M, Zalpuri Reena, Kang Misun, Boone Casadora, Parks Brian W, Zhang Yaohuan, Morgens David W, Newman Emily Tso, Zhou Yingjiang, Talukdar Saswata, Grabe Michael, Ku Gregory, Levine Tim P, Arruda Ana Paula, Olzmann James A

Whole-genome landscapes of 1,364 breast cancers.

1364 例乳腺癌的全基因组图谱。

Kim Ryul, Yu Jonghan, Lim Joonoh, Oh Brian Baek-Lok, Nam Seok Jin, Kim Seok Won, Lee Jeong Eon, Chae Byung Joo, Kim Ji-Yeon, Park Ga Eun, Kang Bong Joo, Paik Pill Sun, Bae Soo Yeon, Yoon Chang Ik, Lee Young Joo, Kim Dooreh, Shin Kabsoo, Lee Ji Eun, Kang Jun, Lee Ahwon, Connolly-Strong Erin, Lee Sangmoon, Lee Bo Rahm, Lee Yuna, Yi Ki Jong, Kwon Young Oh, Chun In Hwan, Park Junggil, Kim Jihye, Choi Chahyun, Shin Jong Yeon, Lee Hyungjung, Kim Minji, Park Hansol, Jeong Ilecheon, Yi Boram, Lee Won-Chul, Lee Jeong Seok, Park Woo Chan, Kim Sung Hun, Choi Yoon-La, Lee Jeongmin, Ju Young Seok, Park Yeon Hee

Targeting FSP1 triggers ferroptosis in lung cancer.

靶向FSP1可诱导肺癌细胞发生铁死亡。

Wu Katherine, Vaughan Alec J, Bossowski Jozef P, Hao Yuan, Ziogou Aikaterini, Kim Seon Min, Kim Tae Ha, Nakamura Mari N, Pillai Ray, Mancini Mariana, Rajalingam Sahith, Han Mingqi, Nakamura Toshitaka, Wang Lidong, Chung Suckwoo, Simeone Diane, Shackelford David, Kang Yun Pyo, Conrad Marcus, Papagiannakopoulos Thales

Myelin is repaired by constitutive differentiation of oligodendrocyte progenitors

髓鞘的修复是通过少突胶质细胞祖细胞的组成性分化实现的。

Mironova, Yevgeniya A; Dang, Brendan; Heo, Dongeun; Xu, Yu Kang T; Hsu, Angela Yu-Huey; Eugenin von Bernhardi, Jaime; Molina-Castro, Gian Carlo; Kim, Anya A; Lin, Jing-Ping; Reich, Daniel S; Bergles, Dwight E

Brain-wide mapping of oligodendrocyte organization, oligodendrogenesis, and myelin injury

全脑少突胶质细胞组织、少突胶质细胞生成和髓鞘损伤的映射

Xu, Yu Kang T; Bush, Abigail; Musheyev, Ephraim; Umans, Jacob; Zhang, Lingzi; Kim, Anya A; Zhang, Sen; Eugenin von Bernhardi, Jaime; Yan, Yuqing; Sulam, Jeremias; Bergles, Dwight E

Microbiome-produced nicotinic acid controls colon regional identity and injury susceptibility.

微生物群产生的烟酸控制结肠区域特性和损伤易感性。

Rispal Jérémie, Garcia Jasmine R, Palikuqi Brisa, Vegesna Manasa, Vaka Dedeepya, Kang Seung Woo, Trentesaux Coralie, Du Juan, Realini Nicola R, Spencer Paige N, Gardner James M, Hausmann Annika, Kattah Michael G, Lau Ken S, Boffelli Dario, Klein Ophir D

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study

厄达替尼或厄达替尼联合西曲利单抗治疗伴有FGFR改变的转移性尿路上皮癌患者:II期NORSE研究的最终结果

Loriot, Yohann; Powles, Thomas; Moreno, Victor; Kang, Taek Won; Cicin, Irfan; Girvin, Angela; Akapame, Sydney; O'Hagan, Anne; Zhu, Wei; Tammaro, Meggan; Thomas, Shibu; Triantos, Spyros; Siefker-Radtke, Arlene O